MAP77

MAP77 is a pre-clinical stage biotechnology company focused on developing novel cancer therapeutics by targeting microtubule-associated proteins. The company's primary focus is on the MAP7 protein, which plays a critical role in microtubule dynamics and intracellular transport, processes often dysregulated in various cancers. By leveraging its proprietary discovery platform, MAP77 aims to identify and optimize small molecule inhibitors that can selectively disrupt the function of MAP7 in tumor cells. This approach is designed to inhibit cell division and induce apoptosis in a range of solid tumors. The company is currently advancing its lead programs through early-stage validation and lead optimization.